GSK (FKA GLAXOSMITHKLINE INC.) for GSK (FKA GLAXOSMITHKLINE INC.)
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
H.R. 3830 - Bipartisan Congressional Trade Priorities Act of 2014; provisions related to trade agreeemnts S. 1900 - Bipartisan Congressional Trade Priorities Act of 2014; provisions related to trade agreeemnts No bill # assigned - Trans-Pacific Strategic Economic Partnership Agreement (TPP); provisions related to intellectual property, market access and public health issues No bill # assigned - Transatlantic Trade and Investment Partnership (TTIP); provisions related to market access intellectual property, regulatory harmonization and other issues No bill # assigned - International market access and intellectual property issues No bill # assigned - Canada IP and market access issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| SHIRA KILCOYNE | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Taxation/Internal Revenue Code TAX
H.R. 4438 - A bill to modify and make permanent the research and development (R&D) tax credit H.R. 5771 - Tax Increase Prevention Act of 2014; provisions related to extension of the research and development tax credit S. 2786 - Corporate Inverters Earnings Stripping Reform Act of 2014; provisions related to Internal Revenue Code section 163(j) No bill # assigned - Tax reform policy issues; provisions related to corporate tax reform and research and development tax credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Copyright/Patent/Trademark CPT
H.R. 2582 - PATENT Jobs Act; provisions related to patent user fees H.R. 2639 - Patent Litigation and Innovation Act; patent litigation proposols H.R. 2766 - STOP Act; provisions related to business method patents H.R. 3116 - MODDERN Cures Act of 2013; Provisions related to exclusivity H.R. 3309 - Innovation Act; provisions related to patent litigation reform H.R. 3349 - Innovation Protection Act; provisions related to PTO fee diversion H.R. 3540 - Demand Letter Transparency Act; provisions related to patent demand letters H.R. 3709 - Protecting Consumer Access to Generic Drugsprovisions related to patent settlements H.R. 4287 - Independent Innovator and Repurposing Act; provisions related to patent term restoration S. 214 - The Preserve Access to Affordable Generics Act; provisions relating to patent settlements S. 504 - Fair and Immediate Release of Generic Drugs Act; provisions related to patent settlements S. 866 - Patent Quality Improvement Act of 2013Business methods patents provisions S. 1013 - Patent Abuse Reduction Act of 2013; provisions related to patent litigation reform S. 1612 - Patent Litigation Integrity Act; Patent litigation provisions including bonding S. 1720 - Patent Transparency and Improvements Act S. 2049 - Transparency in Assertion of Patents Act; Provisions related to patent demand letters S. 2150 - Independent Innovator and Repurposing Act; provisions related to patent term restoration S. 2196 - Patent Fee Integrity Act; patent fee diversion prohibition No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Biologics data protection issues No bill # assigned - Intellectual property issues; Additional data exclusivity request that was part of 21st Century Cures submission
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Health Issues HCR
H.R. 1074 - National Diabetes Clinical Care Commission Act H.R. 1248 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts H.R. 1281 - Newborn Screening Saves Lives Reauthorization Act H.R. 3230 - Veterans' Access to Care through Choice, Accountability, and Transparency Act H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act; provisions related to antibiotics and drug approval H.R. 4260 - Ryan White Patient Equity and Choice Act; provisions related to ADAP H.R. 4847 - End Neglected Tropical Diseases Act S. 539 - National Diabetes Clinical Care Commission Act S. 610 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts S. 1165 - Access to Appropriate Immunizations for Veterans Act of 2013; provisions related to extending VA performance measure to include all federally recommended vaccine S. 1417 - Newborn Screening Saves Lives Reauthorization Act S. 2917 - Adding Ebola to the FDA Priority Review Voucher Program Act No bill # assigned - Implementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking No bill # assigned - 21st Century Cures Initiative and related policy issues No bill # assigned - FDA special medical use; issues related to limited population antibacterial drug approval pathway No bill # assigned - FDA accelerated approval policy issues No bill # assigned - Comparative effectiveness policy issues No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Pharmaceutical supply chain security issues No bill # assigned - 340B policy issues No bill # assigned - Implementation issues relating to the Physician Payment Sunshine Act No bill # assigned - Support for COPD national action plan No bill # assigned - FDA proposed rule regarding generic drug labeling under the 1984 Hatch-Waxman amendments to the FDCA No bill # assigned - FDA proposed rule regarding Electronic Distribution of Content of Labeling for Human Prescription Drug and Biological Products
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Medicare/Medicaid MMM
H.R. 351 - Protecting Seniors' Access to Medicare Act of 2013; provisions related to the Independent Payment Advisory Board H.R. 928 - Medicare Prescription Drug Savings and Choice Act of 2013; provisions related to Medicare Part D H.R. 1024 - Medication Therapy Empowerment Act of 2013; provisions related to Part D issues H.R. 1102 - Medicare Prescription Drug Price Negotiation Act of 2013; Provisions related to Part D issues and non-interference H.R. 1588 - Medicare Drug Savings Act of 2013; provisions related to Part D issues H.R. 2810 - Medicare Patient Access and Quality Improvement Act of 2013; Provisions related to SGR reform H.R. 2827 - To amend title XVIII of the Social Security Act to allow for fair application of the exceptions process for drugs in tiers in formularies in prescription drug plans under Medicare part D; provisions related to Medicare Part D Drug Tier Formularies H.R. 3890 - Better Care, Lower Cost Act; Provisions related to Part D, value-based insurance design, and chronic disease H.R 4160 - Keep the Promise to Seniors Act of 2014; provisions related to Part D H.R. 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act H.R. 4302 - Protecting Access to Medicare Act of 2014; provisions related to the biopharmaceutical industry S. 117 - Medicare Prescription Drug Price Negotiation Act of 2013; provisions related to Part D issues S. 351 - Protecting Seniors' Access to Medicare Act of 2013; provisions related to the Independent Payment Advisory Board S. 408 - Medicare Prescription Drug Savings and Choice Act of 2013; provisions related to Medicare Part D S. 557 - Medication Therapy Empowerment Act of 2013; provisions related to Part D issues S. 740 - Medicare Drug Savings Act of 2013; provisions related to Part D issues S. 1871 - SGR Repeal and Medicare Beneficiary Access Act of 2013; Provisions related to reforming Medicare physician payments S. 1932 - Better Care, Lower Cost Act; Provisions related to Part D, value-based insurance design, and chronic disease S. 2000 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; Provisions related to SGR reform S. 2110 - Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014; Provisions related to SGR reform No bill # assigned - Contract Year 2015 Policy and Technical Cganges to the Medicare Advantage and the Medicare Prescription Drug Benefits Programs; Provisions related to Part D No bill # assigned - Proposals to increase co-payments for Part D beneficiaries receiving the low-income subsidy No bill # assigned - Issues related to better use of medicines and comprehensive medication management No bill # assigned - Medicaid Program, Covered Outpatient Drugs rulemaking No bill # assigned - Implementation Issues relating to the Physician Payment Sunshine ActNo bill # assigned - Vaccine access and coverage issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Budget/Appropriations BUD
H.R. 83 - Making consolidated appropriations for the fiscal year ending September 30, 2015, and for other purposes; provisions related to FDA regulation and funding, sequestration, drug importation, ADAP, BARDA and Section 317 H.R. 4800 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act of 2015; provisions relating to FDA regulation and funding, sequestration, drug importation No bill # assigned - Labor, Health and Human Services, Education and Related Agencies Appropriations Act of 2014; provisions related to ADAP, BARDA and Section 317
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Tariff (miscellaneous tariff bills) TAR
H.R. 6727 - U.S. Job Creation and Manufacturing Competitiveness Act of 2013; provisions related to the emporary duty suspension for preparations, such as tablets or chewing gum, intended to assist smokers to stop smoking (provided for in subheading 2106.90.99)
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| STEPHEN SCANGO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.